Vasculogenic Mimicry in Urothelial Carcinoma

Urothelial Carcinoma Clinical Trial

Official title:

Vasculogenic Mimicry in Urothelial Carcinoma and Its Association With Clinicopathologic Features

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04295967
• Other study ID #: VM in urothelial carcinoma
• Status: Not yet recruiting
• Start date: May 2020
• Est. completion date: May 2022

Study information

• Verified date: March 2020
• Source: Assiut University
• Contact: Ereny K Louis, demonstrator
• Phone: +201023720295
• Email: ereny.kamal14[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, the investigators aim at:

1. Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining.

2. Correlate the presence of vasculogenic mimicry with the clinicopathologic features as age, sex, TNM stage, pathological grade, recurrence, carcinoma in situ, lymphovascular emboli, lymph node metastasis, necrosis, surgical margin, multifocality and tumor size in urothelial carcinoma.

Description:

Bladder cancer is the ninth most common cancer worldwide which seriously affects human health. In Egypt, it is the third common malignant tumor.

Urothelial carcinoma (UC) is considered the most common histologic type of bladder cancer.

It is well recognized that the biological behavior of several cancers is closely related to their blood supply. Tumor progression and metastasis have been long associated with tumor angiogenesis. However, several studies demonstrated that vascular targeting drugs which induce endothelial cell apoptosis have a little effect. So, it has been suggested that novel tumor microcirculation patterns may exist in these neoplasms.

Vasculogenic mimicry (VM), is a novel tumor microcirculation system. Maniotis et al initially discovered VM in melanoma and defined these channels to be composed of tumor basement membrane lined externally by tumor cells, lacking blood vessel endothelium and containing plasma and red blood cells. So VM can be distinguished using immunohistochemical (IHC) staining and histochemical double staining. VM is CD31- or CD34-negative (endothelial markers) and periodic acid-Schiff (PAS) positive.

Vasculogenic mimicry was detected in several malignant tumors. Several studies reported that VM can promote tumor progression and metastasis and it is positively associated with pathological grade, stage, recurrence and drug resistance. Previous studies which evaluate, the role of VM in urothelial carcinoma yield controversial results. So, the value of VM in urothelial carcinomas and its relation to the clinicopathologic parameters remains to be elucidated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: May 2022
• Est. primary completion date: May 2021
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• - Specimens of urothelial carcinoma.

Exclusion Criteria:

• - Any criteria that not fulfill the inclusion criteria such as resected urinary bladder tumors other than urothelial carcinoma.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Urothelial Carcinoma

Intervention

Other:
• formalin fixed paraffin embedded blocks
The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (2)

Aso Y, Ushiyama T, Suzuki K, Tajima A, Naide Y, Ohshima S, Matsuura O, Fukushima M, Ota K, Ono Y, et al. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract]. Nihon Gan Chiryo Gakkai Shi. 1988 May 20;23(5):1046-51. Japanese. — View Citation

Zhou L, Chang Y, Xu L, Hoang ST, Liu Z, Fu Q, Lin Z, Xu J. Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. Oncotarget. 2016 Nov 15;7(46):76214-76223. doi: 10.18632/oncotarget.12775. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining		baseline
Secondary	Correlate the presence of vasculogenic mimicry with the clinicopathologic features in urothelial carcinoma.		baseline